AiCuris Anti-infective Cures GmbH

DGAP-News: AiCuris selects three novel anti-infective treatment approaches as winners of the AiCubator Resident Status, a corporate innovative accelerator initiative

Retrieved on: 
Wednesday, January 13, 2021
Antibiotic, Infection, AiCubator - a new way to collaborate in anti-infectives and support novel approaches, AiCuris Anti-infective Cures GmbH

AiCuris selects three novel anti-infective treatment approaches as winners of the AiCubator Resident Status, a corporate innovative accelerator initiative

Key Points: 
  • AiCuris selects three novel anti-infective treatment approaches as winners of the AiCubator Resident Status, a corporate innovative accelerator initiative
    The issuer is solely responsible for the content of this announcement.
  • "Therefore, we are constantly searching for novel technologies and creative approaches to develop more effective treatments against infectious diseases with high medical needs."
  • "Selmod and the TU Berlin are very honored to be selected as resident in the AiCuris AiCubator program.
  • In the field of antibacterials, AiCuris seeks to develop innovative treatment options for life-threatening, multidrug-resistant, hospital-treated pathogens.

DGAP-News: AiCuris received approval from BfArM to initiate Compassionate Use Program for Pritelivir in Germany

Retrieved on: 
Wednesday, December 2, 2020
Medical specialties, Sexually transmitted diseases and infections, Viral diseases, Purines, Virology, Clinical medicine, Aciclovir, Herpes simplex, Expanded access, Pritelivir, HSV, Compassionate Use Program (CPU), AiCuris Anti-infective Cures GmbH

"Especially in immunocompromised patients, HSV can lead to serious complications," said Dr. Holger Zimmermann, CEO of AiCuris.

Key Points: 
  • "Especially in immunocompromised patients, HSV can lead to serious complications," said Dr. Holger Zimmermann, CEO of AiCuris.
  • At the same time, the data collected in this program will help to bring the drug to patients as quickly as possible and support the planned approval of pritelivir."
  • The Compassionate Use Program in Germany is part of an Early Access Program (EAP) which is operated by myTomorrows, a Netherlands-based HealthTech company facilitating access to medicines in development and real-world data collection.
  • The EAP for treatment of acyclovir-resistant mucocutaneous HSV infections provides immunocompromised patients in different countries worldwide with pre-approval access to pritelivir.

DGAP-News: Royalty Pharma Acquires Partial Royalty Interest on Prevymis(TM) (Letermovir) from AiCuris Anti-infective Cures GmbH

Retrieved on: 
Tuesday, June 9, 2020
Articles, Health, Antibiotic, Royalty payment, Pharmaceutical industry, Bayer, Royalty Pharma, AiCuris Anti-infective Cures GmbH

Founded in 1996, Royalty Pharma is the industry leader in acquiring pharmaceutical royalties.

Key Points: 
  • Founded in 1996, Royalty Pharma is the industry leader in acquiring pharmaceutical royalties.
  • Royalty Pharma is also a leading investor in pre-approval royalties, having since 2011 invested over $5.6 billion in royalties on pre-approval products and committed over $1.2 billion to direct R&D funding in exchange for royalties.
  • For more information, visit www.royaltypharma.com
    AiCuris was founded in 2006 as a spin-off from Bayer and focuses on the discovery and development of drugs targeting infectious diseases.
  • In the field of antibacterials, AiCuris seeks to develop innovative treatment options for life-threatening, multidrug-resistant, hospital-treated pathogens.

DGAP-News: AiCuris was Granted Breakthrough Therapy Designation by U.S. FDA for Pritelivir for the Treatment of HSV Infections in Immunocompromised Patients

Retrieved on: 
Friday, June 5, 2020
Viruses, RTT, Infectious diseases, Medical specialties, Sexually transmitted diseases and infections, Viral diseases, Purines, Herpes, Foscarnet, Aciclovir, Herpes simplex, Breakthrough therapy, Breakthrough Therapy Designation, Pritelivir, HSV, AiCuris Anti-infective Cures GmbH

AiCuris was Granted Breakthrough Therapy Designation by U.S. FDA for Pritelivir for the Treatment of HSV Infections in Immunocompromised Patients

Key Points: 
  • AiCuris was Granted Breakthrough Therapy Designation by U.S. FDA for Pritelivir for the Treatment of HSV Infections in Immunocompromised Patients
    The issuer is solely responsible for the content of this announcement.
  • AiCuris was Granted Breakthrough Therapy Designation by U.S. FDA for Pritelivir for the Treatment of HSV Infections in Immunocompromised Patients
    Wuppertal, June 05, 2020 - AiCuris Anti-infective Cures GmbH, a leading company in the discovery and development of drugs against infectious diseases, today announced that the Company has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for oral pritelivir, AiCuris' lead candidate for the treatment of acyclovir-resistant mucocutaneous herpes simplex virus (HSV) infections in immunocompromised adults.
  • foscarnet, a virostatic agent which is used mainly for the treatment of HSV resistant to other antiviral drugs.
  • With the Breakthrough Therapy designation, AiCuris reached an important milestone and is now looking for a partner for the further development of pritelivir.